In clinical practice, immunohistochemistry‐based estrogen receptor (ER)/progesterone receptor (PgR)/human epidermal growth factor receptor 2 (HER2)/Ki67 examinations can be used to classify breast cancer based on four major subtypes, which are useful for treatment decision‐making.6, 7. Here, ERBB2 is linked to breast carcinoma.